Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy

References

• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–26.
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410–22.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;9:397–405.
   PubMed Web of Science ®Google Scholar
• Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010;86:192–201.
   PubMed Web of Science ®Google Scholar
• Riesenberg K, Levy R, Katz A, Galkop S, Sclaeffer F. Neutrophil superoxide release and interleukin 8 in myocardial infarction: distinction between complicated and uncomplicated states. Eur J Clin Invest 1997;27: 398–404.
   PubMed Web of Science ®Google Scholar
• Matsumori A, Furukawi Y, Hashimoto T, Yoshida A, Ono K, Shioi T, Okada M, Iwasaki A, Nishio R, Matsushima K, Sasayama S. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29:419–23.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97: 1136–43.
   PubMed Web of Science ®Google Scholar
• Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Froland SS, Aukrust P. CXC-chemokines, a new group of cytokines in congestive heart failure – possible role of platelets and monocytes. Cardiovasc Res 2000;45:428–36.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Berge RK, Ueland T, Aaser E, Damas JK, Wikeby L, Brunsvig A, Muller F, Forfang K, Froland SS, Gullestad L. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. Am Coll Cardiol 2001;37:485–91.
   PubMed Web of Science ®Google Scholar
• Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000;21:129–37.
   PubMed Web of Science ®Google Scholar
• Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC-chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999; 143:205–11.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
   PubMed Web of Science ®Google Scholar
• West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440–5.
   PubMed Web of Science ®Google Scholar
• Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648–57.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–4.
   PubMed Web of Science ®Google Scholar
• Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327–32.
   PubMed Web of Science ®Google Scholar
• Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Frøland SS, Haraldsen G, Gullestad L, Damås JK, Hansson GK, Aukrust P. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 2008;28:1005–11.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P;Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175–82.
   PubMed Web of Science ®Google Scholar
• Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia, vascular injury and arterial thrombosis. N Engl J Med 1974;291:537–543.
   PubMed Web of Science ®Google Scholar
• Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arteriscler Thromb Vasc Biol 2002;22: 699–703.
   PubMed Web of Science ®Google Scholar
• Holven KB, Halvorsen B, Bjerkeli V, Damås JK, Retterstøl K, Mørkrid L, Ose L, Aukrust P, Nenseter MS. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke 2006; 37:1731–36.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578–88.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bønaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njølstad I, Nilsen DW, Refsum H, Tverdal A, Vollset SE, Schirmer H, Bleie Ø, Steigen T, Midttun Ø, Fredriksen A, Pedersen ER, Nygård O. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med 2010; 268:367–82.
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354: 1567–77.
   PubMed Web of Science ®Google Scholar
• Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299: 2027–36.
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296:2720–6.
   PubMed Web of Science ®Google Scholar
• Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R; B-Vitamin Treatment Trialists’ Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010 Oct 11;170(18): 1622–31.
   Google Scholar
• Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998;101: 353–63.
   PubMed Web of Science ®Google Scholar
• Rousselle A, Qadri F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, Bader M, Ahluwalia A, Duchene J. CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest 2013;123:1343–7.
   PubMed Web of Science ®Google Scholar
• Alfadda AA, Alzoghaibi MA. Circulatory neutrophil chemokines in statin-treated diabetic patientsSaudi Med J 2008;29:584–8.
   Google Scholar
• Zineh I, Beitelshees AL, Welder GJ, Hou W, Chegini N, Wu J, Cresci S, Province MA, Spertus JA. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS One 2008;3:e3117.
   Google Scholar
• Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 2000;165:2712–8.
   Google Scholar